Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?

WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.

Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?

Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.

Is a Beat in Store for Editas (EDIT) This Earnings Season?

On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.

The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

What's in Store for Vertex (VRTX) This Earnings Season?

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y

Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.

Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Swarup Gupta headshot

5 Biotech Stocks Defying the Medicare-for-All Scare

Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.

Why Is Aduro Biotech (ADRO) Down 10.7% Since Last Earnings Report?

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly (LLY) Signs New Immunology Deal With Private Biotech

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

The Meet Group (MEET) to Report Q4 Earnings: What's in Store?

The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.

Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates

Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.

Top Ranked Momentum Stocks to Buy for February 28th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 28th:

Top Ranked Momentum Stocks to Buy for February 27th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 27th:

Will Aduro Biotech Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

What's in Store for Universal Health (UHS) Q4 Earnings?

Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.

Top Ranked Momentum Stocks to Buy for February 25th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 25th:

What's in Store for Vericel (VCEL) This Earnings Season?

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.

What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.